These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 17979703)

  • 41. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
    Vajkoczy P; Thurnher A; Hirth KP; Schilling L; Schmiedek P; Ullrich A; Menger MD
    Oncologist; 2000; 5 Suppl 1():16-9. PubMed ID: 10804086
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective.
    Paz K; Zhu Z
    Front Biosci; 2005 May; 10():1415-39. PubMed ID: 15769635
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Xiaotan Sanjie decoction inhibits angiogenesis in gastric cancer through Interleukin-8-linked regulation of the vascular endothelial growth factor pathway.
    Shi J; Lu Y; Wei P
    J Ethnopharmacol; 2016 Aug; 189():230-7. PubMed ID: 27224240
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
    Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
    J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
    Song G; Li Y; Jiang G
    Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
    [TBL] [Abstract][Full Text] [Related]  

  • 46. VEGF signaling in cancer treatment.
    Sia D; Alsinet C; Newell P; Villanueva A
    Curr Pharm Des; 2014; 20(17):2834-42. PubMed ID: 23944367
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
    Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
    [TBL] [Abstract][Full Text] [Related]  

  • 48. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
    Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
    Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vascular endothelial growth factor (VEGF) inhibition by small molecules.
    Ahmed SI; Thomas AL; Steward WP
    J Chemother; 2004 Nov; 16 Suppl 4():59-63. PubMed ID: 15688612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
    Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.
    Weigand M; Hantel P; Kreienberg R; Waltenberger J
    Angiogenesis; 2005; 8(3):197-204. PubMed ID: 16328160
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells.
    Ling Y; Yang Y; Lu N; You QD; Wang S; Gao Y; Chen Y; Guo QL
    Biochem Biophys Res Commun; 2007 Sep; 361(1):79-84. PubMed ID: 17644065
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships.
    Boyer SJ
    Curr Top Med Chem; 2002 Sep; 2(9):973-1000. PubMed ID: 12171566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent progress of small molecular VEGFR inhibitors as anticancer agents.
    Xu D; Wang TL; Sun LP; You QD
    Mini Rev Med Chem; 2011 Jan; 11(1):18-31. PubMed ID: 21034401
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure and function of vascular endothelial growth factor and its receptor system.
    Park SA; Jeong MS; Ha KT; Jang SB
    BMB Rep; 2018 Feb; 51(2):73-78. PubMed ID: 29397867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
    Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cross talk between the cardiovascular and nervous systems: neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug development.
    Lazarovici P; Marcinkiewicz C; Lelkes PI
    Curr Pharm Des; 2006; 12(21):2609-22. PubMed ID: 16842161
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 60. VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases.
    Shibuya M
    Endocr Metab Immune Disord Drug Targets; 2015; 15(2):135-44. PubMed ID: 25772179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.